ClinicalTrials.gg

Program

nipocalimab

Also written as “Nipocalimab” and “M281”.

Its studies are mostly in Myasthenia Gravis · Sjogren's Syndrome · Lupus Erythematosus, Systemic · Arthritis, Rheumatoid · Myositis, led by Johnson & Johnson.

Furthest: phase 3, since Sep 18, 201924 company-led studies, 11 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson2411 open or runningphase 3since Sep 18, 2019Jun 14, 2016Dec 15, 2026phase 3 · NCT05327114

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Jun 14, 2016.

  1. Jul 13, 2021Phase 1 study in HealthyNCT04973566 · 48 enrolled · Netherlands
  2. Aug 2, 2021Phase 2 study in Arthritis, RheumatoidNCT04991753 · 53 enrolled · United States, Germany, Poland and more
  3. Dec 7, 2021Phase 1 study in HealthyNCT05151692 · 30 enrolled · China
  4. Feb 22, 2022Phase 3 study in Myasthenia GravisNCT05265273 · 12 planned · United States, Japan, Netherlands and more
  5. Apr 7, 2022Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT05327114 · 201 planned · United States, Argentina, Australia and more
  6. May 17, 2022Phase 2 study in MyositisNCT05379634 · 36 enrolled · United States, Canada, Czechia and more
  7. Jun 13, 2023Phase 3 study in Hemolytic Disease of the Fetus and NewbornNCT05912517 · 120 planned · United States, Argentina, Australia and more
  8. Sep 1, 2023Phase 2 study in Arthritis, RheumatoidNCT06028438 · 103 enrolled · United States, Argentina, Germany and more
  9. Jun 4, 2024Phase 3 study in Thrombocytopenia, Neonatal AlloimmuneNCT06449651 · 39 planned · Belgium, Brazil, France and more
  10. Jul 30, 2024Phase 3 study in Thrombocytopenia, Neonatal AlloimmuneNCT06533098 · 50 planned · United States, Austria, Belgium and more
  11. Dec 18, 2024Phase 3 study in Sjogren's SyndromeNCT06741969 · 655 enrolled · United States, Argentina, Austria and more
  12. Oct 15, 2025Phase 3 study in Myasthenia GravisNCT07217587 · 115 planned · United States, Germany, Israel and more
  13. Feb 23, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07438496 · 600 planned · United States, Argentina, Australia and more
  14. Jun 22, 2026Phase 1 study in HealthyNCT07669077 · 8 planned · United States

Ahead

  1. Dec 15, 2026Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT05327114
  2. Feb 4, 2027Primary completion: phase 3 study in Sjogren's SyndromeNCT06741969
  3. Feb 16, 2027Primary completion: phase 1 study in HealthyNCT07669077
  4. Jun 30, 2027Primary completion: phase 3 study in Myasthenia GravisNCT05265273

TargetBeta

FCGRT →read by rule
“IgG receptor FcRn large subunit p51 antagonist”ChEMBL 37, by rule

Other programs on FCGRT

ProgramCompanyFurthest phaseStudies
efgartigimod alfaruleargenxphase 448
rozanolixizumabruleUCBphase 423
batoclimabruleimmunovant-sciences-gmbhphase 318

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07669077Healthy · United States1RecruitingFeb 16, 20278
NCT07438496Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3RecruitingDec 6, 2028600
NCT07217587Myasthenia Gravis · United States, Germany, Israel and more3RecruitingSep 28, 2027115
NCT06741969Sjogren's Syndrome · United States, Argentina, Austria and more3Active, not recruitingFeb 4, 2027655
NCT06533098Thrombocytopenia, Neonatal Alloimmune · United States, Austria, Belgium and more3RecruitingDec 15, 202750
NCT06449651Thrombocytopenia, Neonatal Alloimmune · Belgium, Brazil, France and more3RecruitingDec 5, 202939
NCT06028438Arthritis, Rheumatoid · United States, Argentina, Germany and more2CompletedAug 29, 2024103
NCT05912517Hemolytic Disease of the Fetus and Newborn · United States, Argentina, Australia and more3RecruitingAug 5, 2027120
NCT05379634Myositis · United States, Canada, Czechia and more2CompletedSep 4, 202536
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more3RecruitingDec 15, 2026201
NCT05265273Myasthenia Gravis · United States, Japan, Netherlands and more3RecruitingJun 30, 202712
NCT05151692Healthy · China1CompletedSep 9, 202230
NCT04991753Arthritis, Rheumatoid · United States, Germany, Poland and more2CompletedAug 10, 202253
NCT04973566Healthy · Netherlands1CompletedMay 27, 202248
NCT04968912Sjogren's Syndrome · United States, France, Germany and more2CompletedOct 23, 2023163
NCT04951622Myasthenia Gravis · United States, Australia, Belgium and more3RecruitingNov 17, 2023199
NCT04883619Lupus Nephritis2WithdrawnFeb 28, 20280
NCT04882878Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more2CompletedApr 30, 2024228
NCT04848558Healthy · Netherlands1CompletedMay 26, 202289
NCT04119050Warm Autoimmune Hemolytic Anemia · United States, Brazil, China and more3Active, not recruitingFeb 2, 2025118
NCT03896295Myasthenia Gravis · United States, Belgium, Canada and more2TerminatedDec 9, 202037
NCT03842189Hemolytic Disease of the Fetus and Newborn · United States, Australia, Belgium and more2CompletedAug 5, 202425
NCT03772587Myasthenia Gravis · United States, Belgium, Canada and more2CompletedJun 25, 202068
NCT02828046Healthy Volunteers · Netherlands1CompletedAug 8, 201750

How it is read

Names in the registry

  • “Nipocalimab”, 19 entries
  • “M281”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.